Athena Athena

X

Find Radio Compass News for Rituximab

PharmaCompass
Related ProductsRelated Products
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-overall-survival-phase-3-trial

PRESS RELEASE
13 Mar 2024

https://www.ema.europa.eu/en/documents/overview/ruxience-epar-medicine-overview_en.pdf

EMA
15 Dec 2023

https://www.globenewswire.com//news-release/2023/12/12/2794525/0/en/ADC-Therapeutics-Announces-Initial-Results-from-Investigator-Initiated-Phase-2-Clinical-Trial-Evaluating-ZYNLONTA-in-Combination-with-Rituximab-in-Patients-with-Relapsed-Refractory.html

GLOBENEWSWIRE
12 Dec 2023

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761103

FDA
16 Oct 2023

https://www.businesswire.com/news/home/20230815559406/en

BUSINESSWIRE
16 Aug 2023

https://www.reuters.com/business/healthcare-pharmaceuticals/obesity-drugs-dont-make-whos-essential-list-ebola-ms-drugs-added-2023-07-26/

REUTERS
27 Jul 2023

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-application-for-biosimilar-candidate-accepted-for-review-by-usfda/articleshow/101704158.cms

ECONOMIC TIMES
13 Jul 2023

https://www.reuters.com/business/healthcare-pharmaceuticals/adc-therapeutics-pauses-enrolment-mid-stage-trial-cancer-therapy-2023-07-11/

REUTERS
12 Jul 2023

https://endpts.com/artiva-boasts-early-nk-cell-therapy-results-giving-lifeline-to-partner-affimed/

Lei Lei Wu ENDPTS
26 May 2023

https://www.globenewswire.com/news-release/2023/05/26/2676842/0/en/Roche-to-present-new-data-in-blood-cancers-and-solid-tumours-from-its-broad-portfolio-at-ASCO-2023.html

GLOBENEWSWIRE
26 May 2023

https://endpts.com/fda-adcomm-votes-11-2-to-expand-roches-polivy-label-in-dlbcl/

Paul Schloesser ENDPTS
10 Mar 2023

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-completes-clinical-studies-of-its-proposed-rituximab-biosimilar-candidate/articleshow/97163863.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

ECONOMIC TIMES
20 Jan 2023

https://www.businesswire.com/news/home/20221212005169/en

BUSINESSWIRE
11 Dec 2022

https://www.fiercepharma.com/pharma/beigene-keeps-momentum-going-brukinsa-winning-nice-recommendation-wm

Kevin Dunleavy FIERCEPHARMA
20 Sep 2022

https://firstwordpharma.com/story/5650882

FIRSTWORLDPHARMA
09 Sep 2022

https://www.thepharmaletter.com/article/fda-accepts-supplemental-biologics-license-application-for-roche-s-polivy-combination

THEPHARMALETTER
17 Aug 2022

https://www.labiotech.eu/trends-news/genentech-lymphoma-treatment/

Jim Cornall LABIOTECH
16 Aug 2022

https://www.businesswire.com/news/home/20220711005186/en

BUSINESSWIRE
11 Jul 2022

https://www.prnewswire.com/news-releases/fda-approves-riabni-rituximab-arrx-a-biosimilar-to-rituxan-rituximab-for-adults-with-moderate-to-severe-rheumatoid-arthritis-301561556.html

PRNEWSWIRE
06 Jun 2022

https://www.expresspharma.in/european-commission-approves-roches-polivy-combination-for-people-with-previously-untreated-diffuse-large-b-cell-lymphoma/

EXPRESS PHARMA
26 May 2022

https://www.reuters.com/business/healthcare-pharmaceuticals/fresenius-agrees-two-acquisition-deals-bolster-kabi-drugs-unit-2022-03-31/

L. Burger REUTERS
01 Apr 2022

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761088

FDA
04 Feb 2022

https://www.businesswire.com/news/home/20220119005536/en

BUSINESSWIRE
19 Jan 2022

https://www.prnewswire.com/news-releases/nordic-nanovector-provides-update-on-paradigme-its-phase-2b-pivotal-trial-with-betalutin-in-rr-follicular-lymphoma-301456433.html

PRNEWSWIRE
07 Jan 2022

http://www.pharmabiz.com/NewsDetails.aspx?aid=144843&sid=2

PHARMABIZ
24 Dec 2021

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705

FDA
17 Dec 2021

https://www.cancernetwork.com/view/progression-free-survival-boost-noted-with-polatuzumab-vedotin-plus-r-chp-for-previously-untreated-dlbcl

CANCERNETWORK
17 Dec 2021

https://www.prnewswire.com/news-releases/i-mab-presents-interim-clinical-data-of-lemzoparlimab-in-combination-with-rituximab-in-relapsed-and-refractory-non-hodgkin-lymphoma-at-ash-2021-301443905.html

PRNEWSWIRE
14 Dec 2021

https://www.businesswire.com/news/home/20211212005018/en

BUSINESSWIRE
12 Dec 2021

https://www.businesswire.com/news/home/20211212005047/en

BUSINESSWIRE
12 Dec 2021

https://www.businesswire.com/news/home/20211211005013/en

BUSINESSWIRE
11 Dec 2021

https://www.prnewswire.com/news-releases/i-mab-to-hold-investor-call-to-present-in-depth-clinical-data-of-lemzoparlimab-in-combination-with-rituximab-in-non-hodgkinss-lymphoma-301440967.html

PRNEWSWIRE
09 Dec 2021

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705

FDA
02 Dec 2021

https://www.businesswire.com/news/home/20211122006027/en

BUSINESSWIRE
22 Nov 2021

https://www.businesswire.com/news/home/20211118005540/en

BUSINESSWIRE
18 Nov 2021

https://c.newsnow.co.uk/A/1104052011?-634:574#out

Shim Woo-hyun NEWSNOW
13 Nov 2021

https://www.globenewswire.com/news-release/2021/11/12/2333443/19219/en/Positive-Recommendation-for-Use-of-TAVNEOS-avacopan-in-ANCA-Vasculitis-Adopted-by-European-Medicines-Agency-EMA-Committee-for-Medicinal-Products-for-Human-Use-CHMP.html

GLOBENEWSWIRE
12 Nov 2021

https://www.prnewswire.com/news-releases/i-mab-to-present-clinical-data-of-lemzoparlimab-in-combination-with-rituximab-in-non-hodgkinss-lymphoma-at-ash-2021-301416284.html

PRNEWSWIRE
04 Nov 2021

https://www.businesswire.com/news/home/20211104005231/en

BUSINESSWIRE
04 Nov 2021

https://www.news-medical.net/news/20211102/Immunocompromised-patients-using-rituximab-could-benefit-from-third-COVID-19-booster-vaccine.aspx

PRNEWSWIRE
02 Nov 2021

http://www.pharmabiz.com/NewsDetails.aspx?aid=142840&sid=2

PHARMABIZ
28 Sep 2021

https://www.chugai-pharm.co.jp/english/news/detail/20210927170000_853.html

PRESS RELEASE
27 Sep 2021

https://endpts.com/chinese-antibody-player-chases-hong-kong-ipo-with-lead-rituxan-challenger-ready-for-late-stage-test/

ENDPTS
19 Jul 2021

https://www.cancertherapyadvisor.com/home/news/conference-coverage/eha2021-virtual-congress/lymphoma-dlbcl-naratuximab-promise-patients-treatment-risk/

CANCERTHERAPYADVISOR
18 Jun 2021

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761064

FDA
15 Jun 2021

https://www.businesswire.com/news/home/20210612005006/fr

BUSINESSWIRE
14 Jun 2021

https://www.prnewswire.com/news-releases/cbmg-holdings-novel-anti-cd20-car-t-cell-therapy-shows-promising-safety-and-efficacy-in-relapsedrefractory-b-cell-non-hodgkin-lymphoma-patients-following-relapse-to-an-anti-cd19-car-t-therapy-301310049.html

PRNEWSWIRE
10 Jun 2021

https://www.prnewswire.com/news-releases/cbmg-holdings-novel-cd19cd20-bi-specific-car-t-cell-product-shows-early-promising-clinical-efficacy-and-favorable-safety-profile-in-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma-301310047.html

PRNEWSWIRE
10 Jun 2021

https://www.prnewswire.com/news-releases/nordic-nanovector-announces-update-from-archer-1-phase-1b-trial-of-betalutin-in-combination-with-rituximab-in-2l-follicular-lymphoma-301298325.html

PRNEWSWIRE
25 May 2021

https://www.newswire.ca/news-releases/health-canada-approves-imbruvica-r-ibrutinib-plus-rituximab-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia-cll--834973397.html

NEWSWIRE
13 Jan 2021
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY